Daiane Britto de Oliveira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daiane Britto de Oliveira has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bárbara Felin Osmari
Laboratório de Tecnologia Farmacêutica, Programa de Pós-Graduação em Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria 97105-900, RS, Brazil
1 shared publication - Camila Parcianello Saccol
Universidade Federal de Santa Maria, Brasil
1 shared publication - Daniela Bitencourt Rosa Leal
Laboratory of Experimental and Clinical Immunobiology, Department of Microbiology and Parasitology, Federal University of Santa Maria, Santa Maria, Brazil.
1 shared publication - Fernanda Licker Cabral
Programa de Residência Multiprofissional em Saúde da Criança e do Adolescente Faculdades Pequeno Príncipe Curitiba Paraná
1 shared publication - Giancarlo Cervo Rechia
Escola de Medicina, Universidade Franciscana, Santa Maria 97010-030, RS, Brazil
1 shared publication - Jéssica Brandão Reolon
Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Farmácia, Universidade Estadual do Centro-Oeste, Guarapuava 85040-167, PR, Brazil
1 shared publication
Latest Publications
- Open Access
- 29 August 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (9) , 2234
Karaya/Gellan-Gum-Based Bilayer Films Containing 3,3′-Diindolylmethane-Loaded Nanocapsules: A Promising Alternative to Melanoma Topical Treatment
This study aimed to incorporate nanocapsules containing 3,3′-diindolylmethane (DIM) with antitumor activity into a bilayer film of karaya and gellan gums for use in topical melanoma therapy. Nanocarriers and films were prepared by interfacial deposition of the preformed polymer and solvent casting methods, respectively. Incorporating DIM into nanocapsules increased its antitumor potential against human melanoma cells (A-375) (IC50 > 24.00 µg/mL free DIM × 2.89 µg/mL nanocapsules). The films were transparent, hydrophilic (θ < 90°), had homogeneous thickness and weight, and had a DIM content of 106 µg/cm2. Radical ABTS+ scavenger assay showed that the DIM films presented promising antioxidant action. Remarkably, the films showed selective bioadhesive potential on the karaya gum side. Considering the mechanical analyses, the nanotechnology-based films presented appropriate behavior for cutaneous application and controlled DIM release profile, which could increase the residence time on the application site. Furthermore, the nanofilms were found to increase the permeation of DIM into the epidermis, where melanoma develops. Lastly, the films were non-hemolytic (hemolysis test) and non-irritant (HET-CAM assay). In summary, the combination of karaya and gellan gum in bilayer films that contain nanoencapsulated DIM has demonstrated potential in the topical treatment of melanoma and could serve as a viable option for administering DIM for cutaneous melanoma therapy.
- 29 August 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (9) , 2234
Open AccessKaraya/Gellan-Gum-Based Bilayer Films Containing 3,3′-Diindolylmethane-Loaded Nanocapsules: A Promising Alternative to Melanoma Topical Treatment
This study aimed to incorporate nanocapsules containing 3,3′-diindolylmethane (DIM) with antitumor activity into a bilayer film of karaya and gellan gums for use in topical melanoma therapy. Nanocarriers and films were prepared by interfacial deposition of the preformed polymer and solvent casting methods, respectively. Incorporating DIM into nanocapsules increased its antitumor potential against human melanoma cells (A-375) (IC50 > 24.00 µg/mL free DIM × 2.89 µg/mL nanocapsules). The films were transparent, hydrophilic (θ < 90°), had homogeneous thickness and weight, and had a DIM content of 106 µg/cm2. Radical ABTS+ scavenger assay showed that the DIM films presented promising antioxidant action. Remarkably, the films showed selective bioadhesive potential on the karaya gum side. Considering the mechanical analyses, the nanotechnology-based films presented appropriate behavior for cutaneous application and controlled DIM release profile, which could increase the residence time on the application site. Furthermore, the nanofilms were found to increase the permeation of DIM into the epidermis, where melanoma develops. Lastly, the films were non-hemolytic (hemolysis test) and non-irritant (HET-CAM assay). In summary, the combination of karaya and gellan gum in bilayer films that contain nanoencapsulated DIM has demonstrated potential in the topical treatment of melanoma and could serve as a viable option for administering DIM for cutaneous melanoma therapy.